Expert review of anticancer therapy

Keyphrases

Publications

volume 24, number 6, 2024

Luca Filaferro, Fabiana Zaccarelli, Giovanni Francesco Niccolini, Andrea Colizza, Federica Zoccali, Michele Grasso, Massimo Fusconi
Are statins onco- suppressive agents for every type of tumor? A systematic review of literature. Expert review of anticancer therapy 24 (6) (2024)
James A Davis, Mary McGann, Jessica Marini, Hamza Hashmi
How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy. Expert review of anticancer therapy 24 (6) (2024)
Silei He, Jiawen Xu, Minlin Chen, Jiajin Li, Shiqian Li, Jufeng Ye
A meta-analysis of UCA1 accuracy in the detection of bladder cancer. Expert review of anticancer therapy 24 (6) (2024)
Maria Gemelli, Adriana Albini, Gianpiero Catalano, Matteo Incarbone, Maria Cannone, Emanuela Balladore, Riccardo Ricotta, Giuseppe Pelosi
Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC. Expert review of anticancer therapy 24 (6) (2024)
Suqi Zhu, Yahan Yu, Mingqi Yang, Xin Liu, Mingkai Lai, Jieren Zhong, Xiaoguang Zhao, Ligong Lu, Yanyan Liu
Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review. Expert review of anticancer therapy 24 (6) (2024)
Hana Študentová, Katerina Hola, Bohuslav Melichar, Martina Spisarova
Neopterin as a potential prognostic and predictive biomarker in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Expert review of anticancer therapy 24 (6) (2024)
Jennifer C Keenan, Arielle J Medford, Charles S Dai, Seth A Wander, Laura M Spring, Aditya Bardia
Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child. Expert review of anticancer therapy 24 (6) (2024)
Hao Hu, Yang Xu, Qiang Zhang, Yuan Gao, Zhenyu Wu
The survival effect of neoadjuvant therapy and neoadjuvant plus adjuvant therapy on pancreatic ductal adenocarcinoma patients with different TNM stages: a propensity score matching analysis based on the SEER database. Expert review of anticancer therapy 24 (6) (2024)
Olalekan O Oluwole, Sattva S Neelapu, Markqayne D Ray, Eve H Limbrick-Oldfield, Sally W Wade, Steve Kanters, Anik R Patel, Frederick L Locke
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies. Expert review of anticancer therapy 24 (6) (2024)
Maria Gemelli, Adriana Albini, Gianpiero Catalano, Matteo Incarbone, Maria Cannone, Emanuela Balladore, Riccardo Ricotta, Giuseppe Pelosi
Navigating resistance to ALK inhibitors in the lorlatinib era: a comprehensive perspective on NSCLC. Expert review of anticancer therapy 24 (6) (2024)
Silei He, Jiawen Xu, Minlin Chen, Jiajin Li, Shiqian Li, Jufeng Ye
A meta-analysis of UCA1 accuracy in the detection of bladder cancer. Expert review of anticancer therapy 24 (6) (2024)
Luca Filaferro, Fabiana Zaccarelli, Giovanni Francesco Niccolini, Andrea Colizza, Federica Zoccali, Michele Grasso, Massimo Fusconi
Are statins onco- suppressive agents for every type of tumor? A systematic review of literature. Expert review of anticancer therapy 24 (6) (2024)

volume 24, number 7, 2024

Junping Lei, Jia Fu, Tianyang Wang, Yu Guo, Mingmin Gong, Tian Xia, Song Shang, Yan Xu, Ling Cheng, Binghu Lin
Molecular subtype identification and prognosis stratification by a immunogenic cell death-related gene expression signature in colorectal cancer. Expert review of anticancer therapy 24 (7) (2024)
Rebecca Romanò, Francesca De Felice, Andrea Ferri, Marco Della Monaca, Roberto Maroldi, Lisa Licitra, Laura Deborah Locati, Salvatore Alfieri
Adenoid Cystic carcinoma of minor salivary glands (AdCCmSG): a multidisciplinary update. Expert review of anticancer therapy 24 (7) (2024)
Meng-Fei Dai, Xin Wang, Wen-Xiu Xin, Si-Si Kong, Wei-Ben Xu, Hai-Ying Ding, Luo Fang
Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis. Expert review of anticancer therapy 24 (7) (2024)
Chiara Deiana, Margherita Agostini, Giovanni Brandi, Elisa Giovannetti
The trend toward more target therapy in pancreatic ductal adenocarcinoma. Expert review of anticancer therapy 24 (7) (2024)
Chiara Ciccarese, Annunziato Anghelone, Alessio Stefani, Antonio Cigliola, Alessandro Strusi, Filippo D'Agostino, Emilio Bria, Roberto Iacovelli, Giampaolo Tortora
The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis. Expert review of anticancer therapy 24 (7) (2024)
Pasquale Vitale, Vincenzo De Falco, Raffaele Addeo
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important? Expert review of anticancer therapy 24 (7) (2024)
Tejpal Gupta, Shakthivel Mani, Abhishek Chatterjee, Archya Dasgupta, Sridhar Epari, Girish Chinnaswamy
Risk-stratification for treatment de-intensification in WNT-pathway medulloblastoma: finding the optimal balance between survival and quality of survivorship. Expert review of anticancer therapy 24 (7) (2024)
Ruiliang Chen, Yushuai Yu, Jie Zhang, Chuangui Song, Chuan Wang
Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis. Expert review of anticancer therapy 24 (7) (2024)
Gianluca Ingrosso, Andrea Lancia, Eleonora Festa, Antonio Rosario Pisani, Rita Bellavita, Cynthia Aristei, Beatrice Detti
The investigational role of cytoreductive stereotactic ablative radiation therapy (SABR) to the primary tumor in metastatic kidney cancer. Expert review of anticancer therapy 24 (7) (2024)
Bahareh Kashani, Zahra Zandi, Atieh Pourbagheri-Sigaroodi, Amir-Mohammad Yousefi, Seyed H Ghaffari, Davood Bashash
The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies. Expert review of anticancer therapy 24 (7) (2024)
Laura Lawaczeck, Julia Rudolph, Valentina Norz, Igor Tsaur, Steffen Rausch
The role of planetary health in urologic oncology. Expert review of anticancer therapy 24 (7) (2024)
Francesca De Felice, Michelangelo Miccini, Andrea Botticelli, Michela Roberto, Niccolò Petrucciani
The multidisciplinary management of locally advanced rectal cancer. Expert review of anticancer therapy 24 (7) (2024)
Ghassan M Saed
Is there a link between talcum powder, oxidative stress, and ovarian cancer risk? Expert review of anticancer therapy 24 (7) (2024)

volume 24, number 8, 2024

Renata Pacholczak-Madej, Michele Bartoletti, Lucia Musacchio, Mirosława Püsküllüoglu, Paweł Blecharz, Domenica Lorusso
Immunotherapy in MMR-d/MSI-H recurrent/metastatic endometrial cancer. Expert review of anticancer therapy 24 (8) (2024)
Wanjin Chen, Shengtao Cheng
Nomogram and calculator for predicting the prognosis of patients with giant hepatocellular carcinoma. Expert review of anticancer therapy 24 (8) (2024)
Thierry Landre, Jean-Baptiste Assié, Kader Chouahnia, Gaetan Des Guetz, Jean-Bernard Auliac, Christos Chouaid
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR -mutated NSCLC: a meta-analysis of randomized phase III trials. Expert review of anticancer therapy 24 (8) (2024)
Gulrayz Ahmed, Fateeha Furqan, Elham Nasrollahi, Mehdi Hamadani
Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma. Expert review of anticancer therapy 24 (8) (2024)
Alfonso Duenas-Gonzalez, Aurora Gonzalez-Fierro, Leticia Bornstein-Quevedo, Francisco Gutierrez-Delgado, Richard E Kast, Alma Chavez-Blanco, Guadalupe Dominguez-Gomez, Myrna Candelaria, Adriana Romo-Pérez, Jose Correa-Basurto, Marcela Lizano, Veronica Perez-de la Cruz, Benjamin Robles-Bañuelos, David Nuñez-Corona, Erandi Martinez-Perez, Emma Verastegui
Multitargeted polypharmacotherapy for cancer treatment. theoretical concepts and proposals. Expert review of anticancer therapy 24 (8) (2024)
Alex Andrea Francoeur, Virginia E Fontenot, Krishnansu Sujata Tewari
Treatment options in the advanced and recurrent setting for endometrial cancer: an update. Expert review of anticancer therapy 24 (8) (2024)
Shalini Srivastava, Sanjay Singh, Ajay Singh
Augmenting the landscape of chimeric antigen receptor T-cell therapy. Expert review of anticancer therapy 24 (8) (2024)
Alessandro Strusi, Giada Pinterpe, Chiara Ciccarese, Romina Rose Pedone, Michele Sarcina, Valeria Sardaro, Rachele Belletto, Angelo Totaro, Marco Racioppi, Rossana Berardi, Giampaolo Tortora, Roberto Iacovelli
Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer. Expert review of anticancer therapy 24 (8) (2024)
Elena Giudice, Vanda Salutari, Carolina Maria Sassu, Viola Ghizzoni, Maria Vittoria Carbone, Laura Vertechy, Anna Fagotti, Giovanni Scambia, Claudia Marchetti
Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives. Expert review of anticancer therapy 24 (8) (2024)
Viria Beccia, Daniela Arduini, Roberto Iacovelli, Alessandro Scala, Denis Occhipinti, Chiara Ligato, Luigi Roca, Pierluigi Russo, Nazario Foschi, Giampaolo Tortora, Chiara Ciccarese
2024 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma. Expert review of anticancer therapy 24 (8) (2024)
Lauren M Lim, Hadi Erfani, Katelyn B Furey, Koji Matsuo, X Mona Guo
Risks and benefits of sentinel lymph node evaluation in the management of endometrial intraepithelial neoplasia. Expert review of anticancer therapy 24 (8) (2024)
Lorenzo Foffano, Riccardo Vida, Alberto Piacentini, Elisabetta Molteni, Linda Cucciniello, Lucia Da Ros, Buriolla Silvia, Lorenzo Cereser, Rossana Roncato, Lorenzo Gerratana, Fabio Puglisi
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? Expert review of anticancer therapy 24 (8) (2024)
Martin Zarba, Ryo Fujiwara, Takeshi Yuasa, Fumitaka Koga, Daniel Y C Heng, Kosuke Takemura
Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review. Expert review of anticancer therapy 24 (8) (2024)

volume 24, number 9, 2024

Udhayvir S Grewal, Shiva J Gaddam, Muhammad S Beg, Timothy J Brown
Targeted therapies in advanced biliary malignancies: a clinical review. Expert review of anticancer therapy 24 (9) (2024)
Genevieve S Silva, Ellen J Kim, Stefan K Barta, Jina Chung
Immune-related adverse events associated with mogamulizumab: a comprehensive review of the literature. Expert review of anticancer therapy 24 (9) (2024)
Stefano Radaelli, Alessandra Merlini, Misbah Khan, Alessandro Gronchi
Progress in histology specific treatments in soft tissue sarcoma. Expert review of anticancer therapy 24 (9) (2024)
Peter D Zang, Allen Seylani, Evan Y Yu, Tanya B Dorff
PROTACing the androgen receptor and other emerging therapeutics in prostate cancer. Expert review of anticancer therapy 24 (9) (2024)
Morando Soffritti
Understanding the link between aspartame and cancer. Expert review of anticancer therapy 24 (9) (2024)
Sarah Al-Jilaihawi, Filippo Spreafico, Annelies Mavinkurve-Groothuis, Jarno Drost, Daniela Perotti, Christa Koenig, Jesper Brok
Bevacizumab-containing treatment for relapsed or refractory Wilms tumor. Expert review of anticancer therapy 24 (9) (2024)
Luca Arecco, Roberto Borea, Isotta Martha Magaton, Kristina Janković, Elene Mariamizde, Mihaela Stana, Graziana Scavone, Silvia Ottonello, Stefano Spinaci, Carlo Genova, Evandro de Azambuja, Matteo Lambertini
Current practices in oncofertility counseling: updated evidence on fertility preservation and post-treatment pregnancies in young women affected by early breast cancer. Expert review of anticancer therapy 24 (9) (2024)
Min Chen, Yijun Qi, Shenghua Zhang, Yubo Du, Haodong Cheng, Shegan Gao
Screening of genes related to programmed cell death in esophageal squamous cell carcinoma and construction of prognostic model based on transcriptome analysis. Expert review of anticancer therapy 24 (9) (2024)
Pierre Peterlin, Esma Saada-Bouzid, Mor Moskovitz, Arnaud Pigneux, Junichiro Yuda, Mahipal Sinnollareddy, William R Henner, Diana Chen, Kevin J Freise, Rachel S Leibman, Abraham Avigdor, Toshio Shimizu
First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC. Expert review of anticancer therapy 24 (9) (2024)
Waseem Jerjes
Elevated DKK1 expression: a promising prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma. Expert review of anticancer therapy 24 (9) (2024)
Stefano Molica, Francesca Romana Mauro
The new life of ibrutinib therapy in CLL: enhancing personalized approaches. Expert review of anticancer therapy 24 (9) (2024)
Jialin Zhang, Jingyang Su, Yeyue Zhou, Jinhua Lu
Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review. Expert review of anticancer therapy 24 (9) (2024)